Skip to main content
MLTX
NASDAQ Life Sciences

MoonLake Submits BLA to FDA for Sonelokimab in Hidradenitis Suppurativa

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.811
Mkt Cap
$995.748M
52W Low
$6.08
52W High
$23.29
52W Position info
94% above low
Off High info
49% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

MLTX sits 94% above its 52-week low of $6.08.

Summary

MoonLake Immunotherapeutics submitted a BLA to the FDA for sonelokimab in moderate-to-severe hidradenitis suppurativa, with FDA acceptance expected within ~60 days and a review timeline within ~74 days.


Key Events · Product Development and Regulatory · MLTX

  • BLA Submitted to FDA

    A Biologics License Application has been submitted for sonelokimab, targeting moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 years and older.

  • FDA Acceptance Timeline

    FDA notification of BLA acceptance is expected within approximately 60 days, with the planned review timeline to follow within approximately 74 days.

  • Expanded Indication Opportunity

    This BLA targets hidradenitis suppurativa, a separate indication from the psoriatic arthritis data announced in August, broadening sonelokimab's commercial potential.

  • Cash Runway Supports Launch

    With $537 million in cash as of Q2 2026 funding operations into mid-2028, sufficient capital is available to support potential commercialization.


Analysis · MLTX · Life Sciences

A major regulatory milestone has been reached with the submission of MoonLake's first Biologics License Application to the FDA, seeking approval of sonelokimab for moderate-to-severe hidradenitis suppurativa. This moves the company from clinical-stage to potential commercialization. The FDA is expected to confirm acceptance within about 60 days and provide a review timeline within about 74 days. The submission follows positive Phase 3 IZAR-1 data in psoriatic arthritis announced in August, but this BLA targets a different indication — hidradenitis suppurativa — expanding the drug's commercial opportunity. With $537 million in cash funding operations into mid-2028, the company is well-positioned to support a launch if approved.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLTX was trading at $11.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $995.7M. The 52-week trading range was $6.08 to $23.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLTX - Latest Insights

MLTX
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $12.45 info
Change: +$0.8481 (+7%) info
Market Cap: $1.064B info
MLTX
Nov 04, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.62
Real-time Price: $12.45 info
Change: +$0.8281 (+7%) info
Market Cap: $1.064B info
MLTX
Nov 04, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $12.45 info
Change: +$0.8381 (+7%) info
Market Cap: $1.064B info
MLTX
Aug 10, 2026, 1:21 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $17.11
Real-time Price: $12.45 info
Change: -$4.66 (-27%) info
Market Cap: $1.064B info
MLTX
Aug 10, 2026, 7:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.19
Real-time Price: $12.45 info
Change: -$3.74 (-23%) info
Market Cap: $1.064B info